HHS allows small pharmacies to compound six unapproved peptides
The Trump administration announced that the Department of Health and Human Services will permit compounding pharmacies to make six specific peptides without FDA approval.
New rules for compounding pharmacies
The Department of Health and Human Services issued a decision allowing small compounding pharmacies to prepare six popular peptides. These substances have not received approval from the Food and Drug Administration yet. The administration stated this change addresses requests from healthcare providers who need these specific treatments.
Potential supply limitations remain
Officials noted that the new permission may not fully satisfy current market demand for these drugs. Some patients might still face difficulties finding available stock despite the regulatory shift. The scope of the allowance is limited strictly to those six specific peptide types.
Regulatory status stays unchanged
The Food and Drug Administration has not changed its stance on approving these substances for general use. Compounding pharmacies must continue to follow existing safety protocols while preparing the permitted peptides. This decision applies only to small facilities rather than large pharmaceutical manufacturers.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.